DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia

Despite significant advances in the treatment of acute myeloid leukemia (AML) the long-term prognosis remains relatively poor and there is an urgent need for improved therapies with increased potency and tumor selectivity. Mylotarg is the first AML-targeting drug from a new generation of antibody dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Carr, Michael I., Zimmermann, Astrid, Chiu, Li-Ya, Zenke, Frank T., Blaukat, Andree, Vassilev, Lyubomir T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031257/
https://www.ncbi.nlm.nih.gov/pubmed/32117773
http://dx.doi.org/10.3389/fonc.2020.00127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031257/
https://www.ncbi.nlm.nih.gov/pubmed/32117773
http://dx.doi.org/10.3389/fonc.2020.00127

Ejemplares similares